Form 4 for ALXO ALX ONCOLOGY HOLDINGS INC
Accepted 2025-03-18 00:00:00 ET · period of report 2025-03-14 · accession 0001415889-25-008417 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-18 | 2025-03-14 | ALXO | Lettmann Jason | CEO, Dir | A - Grant | $0.00 | +42.0K | 212.3K | +25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-14 | A | A | 42,000 | $0.00 | 212,270 | D | — | — | (F1) The reported shares are represented by performance share units, or PSUs, and were awarded upon the achievement of certain performance metrics related to the positive results for ASPEN-06 clinical trials. Shares subject to the PSU vest on March 14, 2026. |